16 results about "Alcohol dependence" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of an expression inhibitor of an NR4A1 gene in preparation of a medicine for treating wine-dependent withdrawal. It is found that after wine-dependent withdrawal, mice have anxiety behaviors, the NR4A1 level of the prefrontal lobe is increased, and apoptosis-related protein in the prefrontal lobe is increased. Knockout of the forehead NR4A1 gene intervenes the expression level of the NR4A1 gene in the forehead lobe of the mouse, it can be proved that down-regulation of the expression of the forehead lobe NR4A1 gene can rescue apoptosis and damage, caused by alcohol, of cortical neurons of the forehead lobe, relieve anxiety behaviors caused by alcohol withdrawal of the mouse, and have the effect of protecting the brain of the mouse; the inhibitor DIM-C-pPhOH of the NR4A1 protein can reduce the expression of the NR4A1 gene of the prefrontal lobe of an alcohol withdrawal mouse and anxiety-like behaviors caused by alcohol withdrawal, and provides related therapeutic targets and new therapeutic drugs for anxiety dysfunction caused by clinical alcohol dependence and alcohol dependence withdrawal.

A method is provided for treating or preventing alcohol dependence and / or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):or a hydrates, a solvate, a pharmaceutically acceptable salt, a prodrug, or a complex thereof to a subject in need thereof. For example, (3S, 4R)-3-((R)-(1-hydroxy-ethyl)-4-((R)-[1-methyl-2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-azetidin-2-one (MC-100093) is an exemplary compound. The composition can be used to prevent or treat alcohol dependence, attenuate alteration in glutamate transporters, reduce alcohol associated neuroinflammation, and treat or prevent alcohol associated fatty liver diseases.

The invention discloses a medical intelligent treatment system, and relates to the technical field of treatment systems. The system comprises a data integration and analysis module, the output end and the input end of the data integration and analysis module are electrically connected with an emotion recognition module, and the output end and the input end of the data integration and analysis module are electrically connected with a psychological support and intervention module. Through multi-module cooperation, an emotional disorder symptom network is constructed, a core intervention node is accurately determined, the drug treatment accuracy is improved, adverse effects caused by individual differences are reduced, an exclusive emotion regulation scheme is formulated through the personalized intervention scheme generation sub-module, for example, specific courses are customized for patients associated with anxiety and wine dependence, and meanwhile, the emotion regulation effect is improved. The longitudinal dynamic analysis sub-module continuously tracks patient data, updates a symptom network model every two weeks, timely captures subtle changes of illness conditions, and comprehensively meets complex and diversified treatment requirements of wine-dependent patients.

The invention belongs to the technical field of medicines, and discloses a ligustrazine derivative modified based on a monosaccharide structural unit and a preparation method of the ligustrazine derivative. According to the invention, a monosaccharide structural unit is introduced to carry out glycosylation modification on ligustrazine molecules, so that the water solubility, the biological activity and the drug effect durability of ligustrazine are remarkably improved, and the pharmacological characteristics of ligustrazine are optimized; the glycosylation modification not only can improve the solubility and stability of ligustrazine, but also can improve the treatment effect of the ligustrazine in specific diseases (such as alcohol addiction and the like) by increasing the affinity of the ligustrazine to a specific target spot; through the technical scheme, the defects of the existing ligustrazine derivative in the aspects of bioavailability, drug effect persistence and the like can be overcome, and the treatment effect and clinical application value of the ligustrazine derivative are remarkably enhanced; the glycosylated and modified ligustrazine derivative has better targeting property and stability, is suitable for wider clinical treatment requirements, and particularly shows greater application potential in treatment of diseases such as alcohol dependence.

The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.

A system for detecting alcoholism using EEG signal processing, comprising: an EEG signal acquisition module configured to acquire digitized EEG signals from a plurality of electrodes placed on the scalp of a subject according to a 10-20 electrode placement system; a signal preprocessing module operationally connected to the EEG signal acquisition module and configured to preprocess the acquired digitized EEG signals, the preprocessed EEG signals being stored in a database containing signals from both alcohol-dependent and control subjects;a computing unit comprising at least one processor with dedicated memory, wherein the processor is configured to receive the preprocessed digitized EEG signals and perform a multi-resolution signal decomposition based on the discrete cosine harmonic wavelet packet transform (DCHWPT) to generate transformed signal representations corresponding to different frequency subbands; a feature extraction module connected to the computing unit and configured to extract a variety of features from the transformed signal representations; a feature selection module configured to perform a statistical test to reduce the dimensionality of the extracted features and retain only relevant features;a classification module configured to categorize EEG signals into an alcoholic or control category based on the retained relevant features; and an output module connected to the classification module, the output module comprising a user interface configured to display the classified results to the user.

The invention discloses a pharmaceutical composition and application thereof in preparation of a medicine for treating alcohol dependence, and belongs to the technical field of biological medicines. The pharmaceutical composition comprises effective amounts of epimedin B, genistein and sipeimine as effective components. The medicine composition has the characteristics of good curative effect, low toxic and side effects and the like. The medicine composition can effectively reverse the preference of alcohol-dependent animals on alcohol, improve the viability of human nerve cells under alcohol exposure, repair nerve cell damage caused by alcohol, regulate the expression quantity of ACHE genes and CHAT genes of cholinergic systems of the alcohol-dependent animals, improve the oxidative stress state caused by alcohol exposure, and improve the curative effect of alcohol-dependent animals on alcohol. The composition has little influence on food intake of alcohol-dependent animals, and can be used for treating alcohol dependence. The invention is helpful for promoting the research and development process of new drugs for alcohol dependence, and provides a new way for scientific development and utilization of resources of traditional Chinese medicinal materials such as herba epimedii and fritillaria fraxini.

Therapeutic methods and models for use of compounds represented by Structural Formula l-VIII and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, isotopic variations including at least one deuterium atom, and N-oxide thereof for treating alcohol abuse, alcohol addiction or alcohol dependency, alcohol-use disorders and their consequences especially cardiometabolic abnormalities, and fibrotic and inflammatory conditions related to the liver and pancreas in an animal or individual. The therapeutic methods and models relate to use of compounds with favorable in vivo pharmacodynamic profiles towards reducing voluntary alcohol (ethanol) intake and seeking behavior in both male and female subjects.

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Provided herein are prodrugs of opioid receptor antagonists such as samidorphan, methocinnamox, and naloxone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases and disorders such as a depressive disorder, alcohol dependence and opioid dependence.

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

The disclosure is directed to, in part, compounds, or pharmaceutically acceptable salts or solvates thereof, for modulating the activity of aldehyde dehydrogenase such as ALDH2 and / or methods for treating and / or preventing an alcohol related disorder such as alcohol use disorder, alcohol induced disorder, alcohol abuse, alcohol dependence, alcohol intoxication, alcohol withdrawal, and the like and / or methods for reducing the amount of alcohol consumed, reducing alcoholic cravings, or increasing the percentage of no heavy drinking days for a subject with alcohol use disorder.

The invention relates to the field of medical biology, in particular to a biological preparation for inhibiting the alcohol drinking amount of an alcohol-dependent person and application of the biological preparation. The invention discloses a biological agent for inhibiting the alcohol drinking amount of an alcohol-dependent person. The biological agent is lactobacillus plantarum extracellular vesicles. The lactobacillus plantarum extracellular vesicles play a role in regulating and controlling the drinking amount of alcohol-dependent rats by regulating the expression of the BNDF, the lactobacillus plantarum extracellular vesicles can increase the expression of the BDNF of PC12 cells in an in-vitro cell culture experiment, alcohol reduces the expression of the BDNF of the PC12 cells, and the lactobacillus plantarum extracellular vesicles achieve the inhibition effect by reversing the expression of the alcohol on the BDNF of the PC12 cells. According to the biological preparation for inhibiting the alcohol drinking amount of the alcohol-dependent person and the application of the biological preparation, SD male rats serve as research objects, the inhibiting effect of extracellular vesicles derived from intestinal lactobacillus plantarum on the alcohol drinking amount of the alcohol-dependent rats and related mechanisms are researched, and a new thought is provided for clinical prevention and treatment of alcohol dependence.

The application discloses a kind of pharmaceutical composition and its purposes in preparation for inhibiting the autonomous intake preference of ethanol. The pharmaceutical composition includes lorcaserin and midazolam. The pharmaceutical composition for inhibiting the autonomous intake preference of ethanol provided by the application can effectively reduce the desire of body to alcohol, is used to treat alcohol dependence, and has significant long-acting characteristics. When the pharmaceutical composition is administered to mice, the absolute amount of active ethanol intake of mice and the relative proportion of ethanol intake compared with the amount of drinking water can be significantly reduced, and the inhibitory effect can last at least 6 days, which is expected to update the treatment plan for alcohol addiction in clinic.

Provided herein is a method for weaning a subject suffering from a drug addiction or addictive behaviors involving opioid signaling by sequentially blocking peripheral and CNS opioid receptors and modulating opioid dependence.

Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and / or opioid antagonists, which demonstrate CNS activity and / or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders.